Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | STAT1 | P42224 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | EDNRB | P24530 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1356271 | 0.86 | AKR1C3 (0.52) | CES2CES1LMNAPARP1NPC1 | |
| SCHEMBL1546686 | 0.83 | CES2 (0.50) | CES2CES1LMNAPARP1NPC1 | |
| SCHEMBL18231508 | 0.81 | MAPT (0.56) | CES2CES1LMNAPARP1NPC1 | |
| SCHEMBL3507981 | 0.81 | NPC1 (0.49) | CES2CES1LMNAPARP1NPC1 | |
| SCHEMBL25460833 | 0.79 | NPC1 (0.47) | CES2CES1LMNAPARP1NPC1 | |
| SCHEMBL1368545 | 0.78 | CES2 (0.49) | CES2CES1LMNAPARP1NPC1 | |
| SCHEMBL6288739 | 0.78 | CES2 (0.49) | CES2CES1LMNAPARP1NPC1 | |
| SCHEMBL8178552 | 0.78 | KDM4E (0.47) | CES2CES1LMNAPARP1NPC1 | |
| SCHEMBL6670315 | 0.77 | HSD17B1 (0.50) | LMNAPARP1MAPTKMT2AALDH1A1 | |
| SCHEMBL6671750 | 0.77 | KIF11 (0.43) | LMNAPARP1SMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004026293-A2 | HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | CES2 1226/4885CES1 1678/4885LMNA 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.